Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry

• DOI: 10.1161/circinterventions.121.011302
• Publication Date: 2022-03-03T10:00:24Z
• Authors: Mirjam G. Wild; Edith Lubos; Ignacio Cruz-Gonz...; Ignacio Amat-Santos; Marco Ancona; Martin Andreas; Niklas F. Boeder; Christian Butter; Fernando Carrasco...; Rodrigo Estevez-L...; Jörg Kempfert; Benedikt Köll; Matteo Montorfano; Holger M. Nef; Stefan Toggweiler; Axel Unbehaun; Paul Werner; Stephan Windecker; Fabien Praz
• Keywords: Peripheral edema

Background: Patients with severe tricuspid regurgitation present late and are often ineligible for surgery or transcatheter repair systems. Transfemoral venous implantation of a bicaval valved stent has been proposed as therapeutic option in selected patients. The aim this study was to summarize the early procedural clinical outcomes novel TRICENTO system treatment patients symptomatic regurgitation. Methods: All consecutive treated custom-made implant at participating centers were included retrospective multicentre registry. Results: A total 21 high-risk (mean age 76±7 years; 67% female) higher grade analyzed. majority New York Heart Association class III/IV (95%), had peripheral edema previous hospitalization right heart failure (67%). Technical success 100%, there no case in-hospital mortality. During follow-up (median 61 days), improvement observed (65% I/II; P <0.001). Computed tomography revealed asymptomatic fractures prosthesis 3 Cardiac magnetic resonance imaging obtained 7 showed significant decrease (252±65 mm baseline versus 216±58 follow-up, =0.006) ventricular end-diastolic volume. overall-survival rate 76% 1 year. Conclusions: data indicate feasibility transfemoral Functional signs reverse remodeling observed. Stent did not impair valve function, but require refinement design careful assessment eligibility criteria.